588 related articles for article (PubMed ID: 26775592)
1. The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer.
Guerrero E; Ahmed M
Lung Cancer; 2016 Feb; 92():22-8. PubMed ID: 26775592
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
[TBL] [Abstract][Full Text] [Related]
3. Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Juan O; Popat S
Clin Lung Cancer; 2017 Nov; 18(6):595-606. PubMed ID: 28377206
[TBL] [Abstract][Full Text] [Related]
4. The evolving role of radiotherapy in treatment of oligometastatic NSCLC.
Bergsma DP; Salama JK; Singh DP; Chmura SJ; Milano MT
Expert Rev Anticancer Ther; 2015; 15(12):1459-71. PubMed ID: 26536370
[TBL] [Abstract][Full Text] [Related]
5. [Stereotactic body radiation radiotherapy for oligometastatic non-small cell lung cancer (NSCLC): A case report].
Leduc C; Antoni D; Quoix É; Noël G
Cancer Radiother; 2015 May; 19(3):192-7. PubMed ID: 25841992
[TBL] [Abstract][Full Text] [Related]
6. SABR for aggressive local therapy of metastatic cancer: A new paradigm for metastatic non-small cell lung cancer.
Westover KD; Iyengar P; Sharma AN; Timmerman R
Lung Cancer; 2015 Aug; 89(2):87-93. PubMed ID: 26028304
[TBL] [Abstract][Full Text] [Related]
7. A Contemporary Update on the Role of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases in the Evolving Landscape of Oligometastatic Disease Management.
Robin TP; Raben D; Schefter TE
Semin Radiat Oncol; 2018 Oct; 28(4):288-294. PubMed ID: 30309639
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
[TBL] [Abstract][Full Text] [Related]
9. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.
Ashworth A; Rodrigues G; Boldt G; Palma D
Lung Cancer; 2013 Nov; 82(2):197-203. PubMed ID: 24051084
[TBL] [Abstract][Full Text] [Related]
10. Radiation therapy for oligometastatic non-small cell lung cancer.
Salama JK; Schild SE
Cancer Metastasis Rev; 2015 Jun; 34(2):183-93. PubMed ID: 25948377
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Body Radiation Therapy for Extracranial Oligometastatic Non-small-cell Lung Cancer: A Systematic Review.
Tsao MN; Ven LI'; Cheung P; Poon I; Ung Y; Louie AV
Clin Lung Cancer; 2020 Mar; 21(2):95-105.e1. PubMed ID: 31959533
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes.
Hadziahmetovic M; Loo BW; Timmerman RD; Mayr NA; Wang JZ; Huang Z; Grecula JC; Lo SS
Discov Med; 2010 May; 9(48):411-7. PubMed ID: 20515609
[TBL] [Abstract][Full Text] [Related]
13. The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope.
Bansal P; Rusthoven C; Boumber Y; Gan GN
Future Oncol; 2016 Dec; 12(23):2713-2727. PubMed ID: 27467543
[TBL] [Abstract][Full Text] [Related]
14. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer.
Shultz DB; Filippi AR; Thariat J; Mornex F; Loo BW; Ricardi U
J Thorac Oncol; 2014 Oct; 9(10):1426-33. PubMed ID: 25170641
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic radiotherapy in oligometastatic cancer.
Kennedy TAC; Corkum MT; Louie AV
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and management of oligometastatic non-small cell lung cancer.
Patel AN; Simone CB; Jabbour SK
Ther Adv Respir Dis; 2016 Aug; 10(4):338-48. PubMed ID: 27060187
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients.
De Rose F; Cozzi L; Navarria P; Ascolese AM; Clerici E; Infante M; Alloisio M; Testori A; Toschi L; Finocchiaro G; Santoro A; Scorsetti M
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):13-20. PubMed ID: 26385822
[TBL] [Abstract][Full Text] [Related]
20. Oligometastases: history of a hypothesis.
Milano MT; Biswas T; Simone CB; Lo SS
Ann Palliat Med; 2021 May; 10(5):5923-5930. PubMed ID: 32279519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
